Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2005 2
2006 1
2007 1
2008 2
2010 3
2011 5
2012 6
2013 2
2015 3
2016 2
2017 8
2018 10
2019 14
2020 13
2021 13
2022 14
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation.
Gavriilaki E, Mallouri D, Laspa E, Papakonstantinou A, Lazaridou A, Varelas C, Baldoumi E, Giannakopoulou A, Demosthenous C, Vardi A, Bousiou Z, Batsis I, Gkioula G, Anagnostopoulos A, Sakellari I. Gavriilaki E, et al. Among authors: sakellari i. Transplant Proc. 2024 Mar;56(2):380-385. doi: 10.1016/j.transproceed.2023.12.010. Epub 2024 Feb 16. Transplant Proc. 2024. PMID: 38368126 Free article. Clinical Trial.
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
Asteris PG, Gandomi AH, Armaghani DJ, Tsoukalas MZ, Gavriilaki E, Gerber G, Konstantakatos G, Skentou AD, Triantafyllidis L, Kotsiou N, Braunstein E, Chen H, Brodsky R, Touloumenidou T, Sakellari I, Alkayem NF, Bardhan A, Cao M, Cavaleri L, Formisano A, Guney D, Hasanipanah M, Khandelwal M, Mohammed AS, Samui P, Zhou J, Terpos E, Dimopoulos MA. Asteris PG, et al. Among authors: sakellari i. J Cell Mol Med. 2024 Feb;28(4):e18105. doi: 10.1111/jcmm.18105. J Cell Mol Med. 2024. PMID: 38339761 Free PMC article.
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in Adult Allogeneic Hematopoietic Cell Transplantation Recipients.
Gavriilaki E, Bousiou Z, Batsis I, Vardi A, Mallouri D, Koravou EE, Konstantinidou G, Spyridis N, Karavalakis G, Noli F, Patriarcheas V, Masmanidou M, Touloumenidou T, Papalexandri A, Poziopoulos C, Yannaki E, Sakellari I, Politou M, Papassotiriou I. Gavriilaki E, et al. Among authors: sakellari i. Int J Mol Sci. 2023 Dec 23;25(1):231. doi: 10.3390/ijms25010231. Int J Mol Sci. 2023. PMID: 38203404 Free PMC article.
Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.
Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A. Christofi P, et al. Among authors: sakellari i. Cancers (Basel). 2023 Dec 17;15(24):5877. doi: 10.3390/cancers15245877. Cancers (Basel). 2023. PMID: 38136421 Free PMC article. Review.
Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M, Batsis I, Mallouri D, Yannaki E, Anagnostopoulos A, Sakellari I. Papalexandri A, et al. Among authors: sakellari i. Int J Mol Sci. 2023 Nov 7;24(22):16029. doi: 10.3390/ijms242216029. Int J Mol Sci. 2023. PMID: 38003218 Free PMC article.
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.
Gavriilaki E, Nikolousis E, Koravou EE, Dimou-Besikli S, Kartsios C, Papakonstantinou A, Mpanti A, Pontikoglou C, Kalpadaki C, Bitsani A, Tassi I, Touloumenidou T, Chatziconstantinou T, Papathanasiou M, Syrigou A, Ztriva E, Kaiafa G, Mandala E, Mellios Z, Karakasis D, Kourakli A, Symeonidis A, Kapsali E, Papadaki HH, Lalayanni C, Sakellari I. Gavriilaki E, et al. Among authors: sakellari i. Front Med (Lausanne). 2023 Oct 11;10:1226114. doi: 10.3389/fmed.2023.1226114. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37901415 Free PMC article.
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Bouchla A, Papageorgiou SG, Symeonidis A, Sakellari I, Zikos P, Thomopoulos TP, Hatzimichael E, Galanopoulos A, Vyniou NA, Kotsianidis I, Pappa V. Bouchla A, et al. Among authors: sakellari i. Leukemia. 2023 Dec;37(12):2517-2519. doi: 10.1038/s41375-023-02051-3. Epub 2023 Oct 10. Leukemia. 2023. PMID: 37816955 Free PMC article. No abstract available.
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, Halaburda K, Blau IW, Clark A, Kröger N, Griskevicius L, Carlson K, Collin M, Bloor A, Raiola AM, Blaise D, Aljurf M, López-Corral L, Sakellari I, Beguin Y, Wrobel T, de Rosa L, de Lavallade H, Hayden PJ, McLornan D, Chalandon Y, Yakoub-Agha I. Ortí G, et al. Among authors: sakellari i. Transplant Cell Ther. 2024 Jan;30(1):93.e1-93.e12. doi: 10.1016/j.jtct.2023.09.019. Epub 2023 Sep 30. Transplant Cell Ther. 2024. PMID: 37783337 Free article.
101 results